Seven articles were reviewed to determine the safety and immunogenicity of CYD-TDV. To determine the immunogenicity of the vaccine, geometric mean titer (GMT) and seropositive rate to all four serotypes were tabulated. Participants who were flavivirus-seropositive at baseline had higher immune response than flavivirus-naïve participants. Seropositive rate to all four dengue serotypes varied from 65%-100%. To determine the safety and reactogenicity, adverse events following immunization (AEFI) were tabulated for all seven articles. The mean of the AEFIs obtained from the table were compared against the safety profile of other flavivirus vaccines. The safety of CYD-TDV was similar to the licensed Japanese Encephalitis vaccine, ChimeriVax-JE.
The development of CYD-TDV is timely and applauded, but further research is needed in order to improve the vaccine before it can be licensed.
Dengue infection is a major global health concern caused by four antigenically distinct dengue virus serotypes (DEN1-4) of the Flaviviridae family. 1 The World Health Organization (WHO) has classified dengue fever as dengue with or without warning signs and severe dengue disease. The first classification, uncomplicated dengue fever, causes a continuum of disease such as biphasic fever, rash, arthralgia, headache and retro-orbital pain. Severe dengue causes abnormal homeostasis and increased vascular permeability with a mortality risk of 1-5%. The current approach to preventing dengue infections is the control of the primary dengue vectors (Aedes aegypti mosquitoes), but this approach is not cost-effective. 3 Clinical treatment is mainly supportive; it is also expensive and must be initiated early in the development of severe dengue disease. Thus, the scale of the problem and the cost of mosquito-prevention measures make vaccine development a global public health priority.
Natural infection with any of the dengue serotypes generates life-long, serotype-specific neutralizing antibodies, but subsequent reinfection with other serotypes may be associated with increased severity of the disease. 4 Immune complexes formed by non-neutralizing antibodies and secondary dengue infection could be associated with higher viral titres 5 ; thus, it is essential that an ideal vaccine with a good safety profile has the ability to elicit broad and durable protective immunity against all four serotypes. Developing an ideal dengue vaccine has been a challenge due to several factors: 1) Pre-clinical phases of clinical trials have failed to produce typical human-type dengue diseases. 6 2) Each of the four dengue serotypes is capable of producing severe disease and longterm serotype-specific antibodies with only short term cross-protective immunity against other serotypes. 3) The theory of antibody-dependent enhancement (ADE) is associated with more severe secondary infection. 8 
4)
No correlation has been established between neutralizing antibody titres and protection against dengue infection in different age groups due to a lack of clinical trials for vaccine efficacy.
5) There is a lack of an immune response laboratory measurement that can be correlated with protective immunity against dengue infection.
Over the years, many efforts have been made to develop dengue vaccines; the most successful candidate vaccine to date is the Sanofi Pasteur CYD tetravalent dengue vaccine. It is a recombinant live attenuated vaccine that expresses the pre-membrane and envelope genes of the four dengue serotypes (DENV1-4), and the nonstructural and capsid protein of the attenuated yellow fever (17D) vaccine virus. 9 Each 0.5mL dose contains approximately 5 log 10 cell culture infectious dose (CCID 50 ) of each recombinant dengue virus serotype. Generally, trials of this vaccine were administered subcutaneously to the right deltoid of the volunteers in three doses on 0, 6 and 12 months (with the exception of one study in which doses were administered at 0, 4 and 12-15 months).
To date, there is no published review that has assessed the immunogenicity and safety of dengue vaccine candidates. The aim of this work is to review the safety and immunogenicity of CYD-TDV.
The data in this systematic review was collated from several different dengue vaccine clinical trials. We performed an exhaustive search on several online platforms, namely PubMed, ScienceDirect, and OMICS Group.
A review was performed to collect all available English-language literature on the subject, after which the search results were narrowed down using a set of predetermined parameters, which included the keywords "dengue" and "vaccine," and the Boolean connector "AND." The search was further narrowed to only include literature The resulting articles that fit these parameters were then pared down to seven articles that discussed CYD-TDV developed by Sanofi Pasteur (see Figure 1 ).
Immunogenicity
Serum samples were collected before the first injection to determine flavivirus-serostatus of the volunteers and 28 days post-dose 1, 2 and 3 to determine seropositive rate and neutralizing antibody titres, as described in all reviewed articles.
Safety and reactogenicity
Safety and reactogenicity were assessed based on the adverse events (AE) that arise in the study population. As described in all reviewed articles, the investigators collected the data by conducting physical examinations, measuring body temperatures, and taking blood samples of participants during study visits. Participants were also given diary cards to record any adverse events that occurred. Data of the adverse events following immunization (AEFI) are shown in Table 2 . The data for the AEFIs for the seven trials were collated based on the data pooling method. The equation used to pool the data was, n% = !AEFI/!N x 100%, where n% is the pooled percentage of a particular AEFI in the seven trials, !AEFI is the numerical sum of a particular AEFI in the seven trials! and !N is the numerical sum of the participants who were given CYD-TDV in the seven trials.
Usually, the safety of a candidate vaccine can be established by comparing it to a pre-existing licenced vaccine or treatment. However, since the standard of care for dengue is only supportive therapy, the data could not be compared against a baseline safety level. Therefore, we compared the safety of the CYD-TDV vaccine against other licenced flavivirus vaccines (Table 3 ). Baseline flavivirus-seropositive (n/N) = 111/199 (55.8%) ! "! Table 1 . This table shows geometric mean titres (GMTs) for dengue serotype-specific plaque reduction neutralization tests (PRNT 50 ) antibodies before vaccination and 28 days after first, second, and third injections of CYD-TDV. It also shows baseline flavivirus-seropositive (n/N) and seropositive rate for all four dengue serotypes (%). Note: N/A is not available, N is the total number of participants who received CYD-TDV, and n is subset of the sample.
Immunogenicity
Neutralizing antibodies directed against the envelope proteins (E) are considered to be the main mediators of immunity against flavivirus infection, and the demonstration of neutralizing antibodies is a surrogate of protective immunity in clinical trials for vaccine candidates. 22 In vivo and in vitro pre-clinical studies in mice demonstrated that by transferring the immune serum raised against appropriate epitopes of the E proteins, it is possible to confer broadened protection among flaviviruses such as DEN2, YF 17D and tick-borne encephalitis. 23, 24 Pre-clinical studies for immunogenicity in CYD-TDV candidates have been shown to stimulate human dendritic cell maturation in a controlled manner with limited cytokine production, and with stable expression of anti-viral interferon. 9 Additionally, it also elicited significant neutralizing antibodies in monkeys that cross-reacted with approximately 20 different circulating strains per serotype. Prompted by the positive pre-clinical data on immunogenicity and safety, a CYD-TDV live attenuated vaccine has been approved for industrialization in order to fulfill the needs and access for phase I, II and III clinical studies on healthy volunteers. Table 1 shows the studies conducted to determine the immunogenicity of CYD-TDV candidates. The same administration regime and measurements of immunogenicity of CYD-TDV were used in all of the studies. The humoral immune response was assessed using plaque reduction neutralization test (PRNT 50 ) on Vero/ LLC-MK2 cells in accordance with WHO guidelines. 25 Neutralizing antibody titres were expressed as geometric mean titre (GMTs), which is the highest reciprocal serum dilution at Table 2 . The pooled data for participants who experienced AEFI during the study period for all seven studies. Note: N/A is not available, M is mean, and N is the total number of participants who received CYD-TDV.
DISCUSSION
which the mean number of plaques was reduced by 50% when compared with the count obtained from the control well. Seropositivity was defined as antibody titres $ 10 dil -1 and seropositive rate was defined as percentage of participants with titres $ 10 dil . Immune response for the CYD-TDV candidate is expressed in terms of GMT and seropositive rate in the reviewed studies. For the purpose of convenience, this review for immunogenicity of the CYD-TDV vaccine has been further divided into two sections: 1) Immune response after CYD-TDV vaccinations for baseline seropositive-flavivirus participants, and 2) Immune response after CYD-TDV vaccinations induced for different dengue serotypes (DENV1-4).
1) Immune response after CYD-TDV vaccinations for baseline seropositive-flavivirus participants
In all studies, participants were classified as FVseropositive or FV-seronegative at baseline. FV-seropositive individuals had flavivirus antibody titres (s) $ 10 dil -1 for any dengue serotypes, yellow fever or Japanese encephalitis, whereas FV-seronegative individuals had flavivirus antibody titres (s) < 10 dil -1
. FVseropositive at baseline indicates natural exposure to either dengue, other flaviviruses, or the yellow fever/Japanese encephalitis vaccination. The difference between the immune response of FV-seropositive and FV-seronegative individuals after vaccinations was established using a full analysis set (FAS) in the trials. Table 3 . Comparison of AEFI between CYD-TDV and other licenced flavivirus vaccines. Note: N/A is not available and M is mean.
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in the adult group and lowest in the adolescent group. The immune response after vaccinations was noted to be stronger in adults and children compared to adolescents, which suggests that pre-existing flavivirus antibodies have a beneficial effect on the vaccine-induced immune response.
The Sabchareon et al. study reported that more than 90% flavivirus-seropositive participants at baseline exhibited high immune response after CYD-TDV vaccinations. This study may represent an immune response to the CYD-TDV vaccine for individuals typically from endemic areas with various dominant circulating dengue serotypes. The study by Tran et al. reported a high proportion of flavivirus-seropositive participants (76%) receiving the CYD-TDV candidate vaccine. The immune response was higher among those who were seropositive at baseline, and the response increased with the age groups of study. This reaffirms that in a dengue endemic area, age-dependent exposure and high flavivirus -seropositivity level may benefit the dengue vaccine-induced antibody response. The study by Dayan et al. reported majority of participants were flavivirus-seropositive (81%) at baseline. As expected, a higher immune response was detected for flavivirus-seropositive participants at baseline, suggesting an important role of prior flavivirus antibodies in vaccine-induced immunity. The third dose did not increase the immune response in flavivirus seropositive participants compared to first and second doses; however, it may not be statistically significant because of the small sample size and assay variability of the study.
The work conducted by Hss et al., in which more than half of the participants (55.8%) were flavivirus-seropositive at the baseline, reported higher immune response compared to flavivirus-negative participants after CYD-TDV vaccinations. Although the third dose had little impact on immune response, a three-dose regimen was still recommended to induce a balanced immune response especially in a mixed flavivirus-serostatus population. 16 Overall, studies with flavivirus-seropositive participants at baseline have demonstrated that pre-existing antibodies improve vaccine-induced immune response without affecting the ability of the vaccine candidate to produce a balanced antibody response. Due to high serological cross-reactivity that exists between flaviviruses, it's necessary to determine the effect of pre-existing flavivirus antibodies on the immunogenicity of CYD-TDV. This is particularly important in individuals residing in endemic areas who could have been infected with dengue virus prior to vaccination, or who may have also been vaccinated with Japanese encephalitis (JE) or yellow fever (YF) vaccines. 26, 27 The higher immune response among individuals who are flavivirus seropositive against viral heterotypes (JE/YF) can be explained by the crossneutralization theory. This is associated with a greater neutralizing antibody response against cross-reactive antigenic epitope(s), by a mechanism involving molecular mimicry of an epitope presented on the envelope proteins of DENV1-4 which are detected by immune cells. 28 Therefore, it can be speculated that the CYD-TDV vaccine is considered to induce strong, crossreactive neutralizing antibodies which may give durable effective immunity against all four dengue serotypes in flavivirus-seropositive individuals.
2) Immune response after CYD-TDV vaccinations induced for different dengue serotypes (DEN-V1-4).
One of the major challenges in developing a dengue vaccine is to induce balanced neutralizing antibodies to all four dengue serotypes. Morrison et al. reported that all participants (100%) in the study seroconverted against four WHO reference strains with increasing GMT with the number of doses. The first dose induced an immune response mainly against DENV-4 and DENV-2. The second and third doses increased the immune response for all serotypes. Higher immune responses were noted for longer intervals between the second and third dose, which may indicate that longer intervals reduce viral interference between dengue serotypes. 29 The study by Leo et al. reported that in all age groups combined after the third dose, the seropositivity rate and GMT were highest for DENV-4 and lowest for DENV-1. The immune response was higher for DENV-4 and DENV-3 than DENV-1 and DENV2 after the first dose but increased against all serotypes after the third dose. More than half of the participants (66.5%) were seropositive to all four dengue serotypes after three injections.
Sabchareon et al. reported that the immune response was higher than baseline after the first vaccination and further increased after the second and third injections with a small decrease for DENV-2 and DENV-4 post-dose 3. After the third dose, the immune response was highest for DENV-3 and lowest for DENV-1. Given that this was a vaccine efficacy study, an efficacy estimated against DENV-1, 3 and 4 was 70% and was not significant for DENV-2. The study by Tran et al. reported that the immune response increased after each dose for all serotypes in all age cohorts. GMT was highest for DENV-2 and least for DENV-1. 92% of participants were seropositive to all four dengue serotypes after 3 doses of the CYD-TDV vaccine. The research conducted by Dayan et al. reported an increase in GMT in all participants after the first dose and, after the second dose in most cases, except for DENV-4. 96.6% of participants were seropositive for all four serotypes after the third dose of CYD-TDV. Villar et al. reported that the GMT increased after each dose for DENV-1 and 3, increased within first and second doses for DENV-2, and was highest post-dose 1 for serotype 4 with a small decrease for DENV-2 and DENV-4 post-dose 3. Seropositive rates also increased after each injection for all the serotypes. About 93.4% of participants were seropositive for all 4 serotypes after the third dose. The research conducted by Hss et al. reported immune responses only for post-dose 2 and 3 vaccinations, and it claimed robust immune response against all serotypes after vaccination with the highest GMT recorded for DENV-3 and lowest for DENV-4.
An ideal tetravalent dengue vaccine should induce antibodies against all of the serotypes due to theoretical concerns regarding a potential increase in the severity of dengue disease by an incomplete immune response mediated via antibody-mediated enhancement (ADE). 30 Even though all studies have claimed that a three dose regimen of CYD-TDV elicited a good immune response in the cohorts against four dengue serotypes, it's important to note that seropositive rate to all four dengue serotypes varied between studies from a range of 65% to 100%. This would be a concern in a population with a low seropositive rate to the CYD-TDV vaccine, as vaccinated individuals with incomplete immune response may become predisposed to the development of severe dengue manifestations with subsequent dengue virus infections.
Although CYD-TDV induced immune response for all serotypes, it is not known to what extent the GMT detected by PRNT 50 correlates with protection against the disease, as was reported by Sabchareon et al. The efficacy of a vaccine is better measured after it is introduced in the population, but Sabchareon et al. questions if the robustness of immune response after vaccination is a true surrogate of protection, and also questions the reliability of the PRNT 50 measure of neutralizing antibodies using Vero/ LLC-MK2 cells that do not express FcyR. 31 Due to the concerns discussed above, while the development of a CYD-TDV vaccine is support ed, the quality of antibodies such as affinity, functionality, and dengue epitope recognition, as well as the conventional method of measuring DENV neutralization using PRNT 50, deserve further study for a proper measurement of immunogenicity of the CYD-TDV vaccine candidate.
Safety and reactogenicity
When compared to other flavivirus vaccines, the incidence of adverse events tended to be higher in the CYD-TDV group, especially for the solicited injection site reaction (40.4%) and the solicited systemic reaction (55.8%). The most common reaction for the solicited injection site reaction was pain, while the most common side effect for the systemic reaction was headache. In all seven studies, the majority of these events were mild with full recovery within three days. The study by Tran et al. also noted that the rates of solicited systemic reactions decreased after each successive vaccine dose. The incidence of unsolicited AE was also higher in the CYD-TDV group (43.3%), but these figures may not be representative because the unsolicited AE data were not described in most of the other flavivirus vaccine study reports. [17] [18] [19] [20] The incidence of serious AE (which can be defined as "any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/ birth defect, or is an important medical event") was also higher in the CYD-TDV group, but it should be noted that the other flavivirus vaccine studies only included SAEs that were proven to be vaccine related, therefore reducing the overall SAE incidence. 13 The CYD-TDV trials included all of the SAEs that occurred during the study period, most of which were proven to be unrelated to the vaccine by an independent data monitoring committee. 11 Since no vaccine related SAE was reported in any one of the studies, the SAE results of CYD-TDV are not reflective of its safety.
The trials also discussed whether or not the baseline flavivirus status affected the reactogenicity of the CYD-TDV vaccine. Dayan et al. found that the incidence of solicited injection site reaction was higher among baseline flavivirus seropositive individuals, but no differences were noted for other AEs. Conversely, the studies of Villar et al. and Hss et al. noted that baseline flavivirus status did not markedly affect the reactogenicity of the vaccine. These results demonstrate that baseline flavivirus seropositivity does not appear to induce greater reactogenicity compared to the seronegative population. The trials also measured viremias following febrile episodes in the CYD-TDV group.
12,13,15 The incidence of viremia was relatively low or absent in most of the trials; however, as the study by Leo et al. explains, blood samples were not obtained in a timely manner, which might have caused the investigators to miss cases of viremia. The study by Morrison et al. also noted that viremia incidence decreased with each vaccine dose.
The safety and reactogenicity profile of CYD-TDV can be established by comparing it to a similar type of flavivirus vaccine that has been licenced. As demonstrated in Table 3 , the vaccine that was the most similar to CYD-TDV was the Japanese Encephalitis ChimeriVax vaccine. Both vaccines use the same recombinant technology by utilising the attenuated Yellow Fever virus (17D) as the backbone. The regimens for both vaccines are different; CYD-TDV is administered in 3 doses, while ChimeriVax is administered in a single dose. The incidence of any AE is higher with ChimeriVax (88%) compared to CYD-TDV (69.7%). However, as discussed earlier, the incidence of solicited injection site, systemic reaction, and unsolicited AEs are high er in the CYD-TDV group. This might indicate that the reactogenicity of the CYD-TDV is higher compared to ChimeriVax. The incidence of SAE with ChimeriVax is 0.2% while no vaccine related SAE were noted for CYD-TDV, which indicates that the safety of CYD-TDV is probably similar to that of ChimeriVax.
We have reviewed seven relevant studies of a candidate dengue virus vaccine, CYD-TDV for both safety and immunogenicity. Our analysis of the data from the seven studies indicates that is not possible to make any firm conclusion regarding the safety of the vaccine because of the small size of the study population. There was varying immunogenicity, with greatest variation shown amongst subjects with pre-existing flavivirus-seropositivity in all studies. There remains doubt regarding the most appropriate surrogate serological indicator of immunity.
Although the development of the CYD-TDV is applauded and timely, this vaccine candidate still requires further studies and development, particularly in determining the level of reactogenicity that is considered safe and at what level immunogenicity is protective.
